In what has become a red-hot stock market for med-tech stocks, it's the rare quality company that hasn't taken part in the rally. As a huge player in drugs, devices, and OTC consumer healthcare products, Johnson & Johnson(NYSE: JNJ) has certainly been carried along by this healthcare lovefest – the shares are up nearly 40% over the past year, and only a small handful of other large companies (Stryker(NYSE: SYK) and Roche(Nasdaq: RHHBY), for instance) can come close to matching or exceeding Johnson & Johnson.
The curious thing about this performance is that it hasn't accompanied strong, even financial performance. JNJ's drug business has roared back to life, but the device business continues to struggle with a difficult environment and past mistakes, while the consumer business tries to recover from the reputation and market share damage incurred by the spate of recalls and contamination problems a few years ago.
Please read more here:
http://www.massdevice.com/blogs/massdevice/can-johnson-johnson-fire-all-cylinders-again
0 comments:
Post a Comment